Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jan;59(1):31-37.
doi: 10.1007/s00592-021-01789-5. Epub 2021 Aug 27.

Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial

Benjamin J Wheeler  1   2 , Olivia J Collyns  3 , Renee A Meier  4 , Zara L Betts  4 , Chris Frampton  5 , Carla M Frewen  2 , Barbara Galland  2 , Niranjala M Hewapathirana  1 , Shirley D Jones  2 , Denis S H Chan  3 , Anirban Roy  6 , Benyamin Grosman  6 , Natalie Kurtz  6 , John Shin  6 , Robert A Vigersky  6 , Martin I de Bock  7   8   9
Affiliations
Randomized Controlled Trial

Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial

Benjamin J Wheeler et al. Acta Diabetol. 2022 Jan.

Abstract

Background: Automated insulin delivery aims to lower treatment burden and improve quality of life as well as glycemic outcomes.

Methods: We present sub-study data from a dual-center, randomized, open-label, two-sequence crossover study in automated insulin delivery naïve users, comparing Medtronic MiniMed® Advanced Hybrid Closed-Loop (AHCL) to Sensor Augmented Pump therapy with Predictive Low Glucose Management (SAP + PLGM). At the end of each 4-week intervention, impacts on quality of life, sleep and treatment satisfaction were compared using seven age-appropriate validated questionnaires given to patients or caregivers.

Results: 59/60 people completed the study (mean age 23.3 ± 14.4yrs). Statistically significant differences favoring AHCL were demonstrated in several scales (data shown as mean ± SE). In adults (≥ 18yrs), technology satisfaction favored AHCL over PLGM as shown by a higher score in the DTSQs during AHCL (n = 28) vs SAP + PLGM (n = 29) (30.9 ± 0.7 vs 27.9 ± 0.7, p = 0.004) and DTSQc AHCL (n = 29) vs SAP + PLGM (n = 30) (11.7 ± 0.9 vs 9.2 ± 0.8, p = 0.032). Adolescents (aged 13-17yrs) also showed a higher DTSQc score during AHCL (n = 16) versus SAP + PLGM (n = 15) (14.8 ± 0.7 vs 12.1 ± 0.8, p = 0.024). The DTQ "change" score (n = 59) favored AHCL over SAP + PLGM (3.5 ± 0.0 vs 3.3 ± 0.0, p < 0.001). PSQI was completed in those > 16 years (n = 36) and demonstrated improved sleep quality during AHCL vs SAP + PLGM (4.8 ± 0.3 vs 5.7 ± 0.3, p = 0.048) with a total score > 5 indicating poor quality sleep.

Conclusion: These data suggest that AHCL compared to SAP + PLGM mode has the potential to increase treatment satisfaction and improve subjective sleep quality in adolescents and adults with T1D.

Keywords: Adolescents; Automated insulin delivery; Children; Diabetes; Psychosocial; Sleep; Type 1.

PubMed Disclaimer

References

    1. Bekiari E, Kitsios K, Thabit H, Tauschmann M, Athanasiadou E, Karagiannis T et al (2018) Artificial pancreas treatment for outpatients with Type 1 Diabetes: systematic review and meta-analysis. BMJ 361:k1310 - DOI
    1. Collyns OJ, Meier RA, Betts ZL, Chan DSH, Frampton C, Frewen CM et al (2021) Improved glycemic outcomes with medtronic minimed Advanced Hybrid Closed-Loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with Type 1 Diabetes. Diabetes Care 44(4):969–975 - PubMed
    1. Bergenstal RM, Nimri R, Beck RW, Criego A, Laffel L, Schatz D et al (2021) A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 397(10270):208–219 - DOI
    1. Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E et al (2020) A randomized trial of closed-loop control in children with Type 1 Diabetes. N Engl J Med 383(9):836–845 - DOI
    1. Kanapka LG, Wadwa RP, Breton MD, Ruedy KJ, Ekhlaspour L, Forlenza GP et al (2021) Extended use of the control-IQ closed-loop control system in children with Type 1 Diabetes. Diabetes Care 44(2):473–478 - DOI

Publication types

LinkOut - more resources